References of "Gosset, Christiane"
     in
Bookmark and Share    
Peer Reviewed
See detailLa qualité de vie en population générale
Gosset, Christiane ULg

Conference (1999)

Detailed reference viewed: 2 (0 ULg)
See detailMulti-city network on drug mesure trends
Honore, A.; Amraei, M.; Bils, L. et al

Report (1999)

Detailed reference viewed: 5 (0 ULg)
See detailEtude pilote : Case management intégré dans les hôpitaux belges.
de Froidmont, C.; Dejace, Alain ULg; Englebert, L. et al

Report (1999)

Detailed reference viewed: 24 (6 ULg)
See detailConsommation et milieux de vie. Gestion des drogues en 2000
De Ruyver, B.; De Winter, C.; Gosset, Christiane ULg et al

Book published by Maklu/Bruylant (1999)

Detailed reference viewed: 11 (0 ULg)
See detailEstablished postmenopausal osteoporosis – Assessment of treatment options
Reginster, Jean-Yves ULg; Halkin, V.; Fraikin, G. et al

in Menopause Review (1999), 1(IV), 39-55

Detailed reference viewed: 5 (1 ULg)
Full Text
Peer Reviewed
See detailTreatment of Osteoporosis: Role of Bone-Forming Agents
Reginster, Jean-Yves ULg; Halkin, V.; Henrotin, Yves ULg et al

in Osteoporosis International (1999), 9 Suppl 2

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailThe Effect of Sodium Monofluorophosphate Plus Calcium on Vertebral Fracture Rate in Postmenopausal Women with Moderate Osteoporosis. A Randomized, Controlled Trial
Reginster, Jean-Yves ULg; Meurmans, L.; Zegels, Brigitte ULg et al

in Annals of Internal Medicine (1998), 129(1), 1-8

BACKGROUND: Fluoride is effective in increasing trabecular bone mineral density (BMD) in the spine, but its efficacy in reducing vertebral fracture rates and its effect on BMD at cortical sites are ... [more ▼]

BACKGROUND: Fluoride is effective in increasing trabecular bone mineral density (BMD) in the spine, but its efficacy in reducing vertebral fracture rates and its effect on BMD at cortical sites are controversial. OBJECTIVE: To study the effect of low-dose fluoride (sodium monofluorophosphate [MFP]) plus a calcium supplement over 4 years on vertebral fractures and BMD at the lumbar spine and total hip in postmenopausal women with moderately low BMD of the spine. DESIGN: Randomized, double-blind, controlled clinical trial. SETTING: Outpatient clinic for osteoporosis at a university medical center. PATIENTS: 200 postmenopausal women with osteoporosis (according to the World Health Organization definition) and a T-score less than -2.5 for BMD of the spine. INTERVENTION: Women were randomly assigned (100 patients per group) to continuous daily treatment for 4 years with 1) oral MFP (20 mg of equivalent fluoride) plus 1000 mg of calcium (as calcium carbonate) or 2) calcium only. MEASUREMENTS: Lateral spine radiographs were taken at enrollment and at each year of follow-up for detection of new vertebral fractures (defined as a reduction > or =20% and > or =4 mm from baseline in any of the heights of a vertebral body). Nonvertebral fractures were also recorded. All analyses were done with the intention-to-treat approach. RESULTS: Radiologic follow-up was possible for 164 of 200 patients (82%). The rate of new vertebral fractures during the 4 years of the study was lower in the MFP-plus-calcium group (2 of 84 patients; 2.4% [95% CI, 0.3% to 8.3%]) than in the calcium-only group (8 of 80 patients; 10% [CI, 4.4% to 18.8%]). The difference between the groups was 7.6 percentage points (CI, 0.3 to 15 percentage points) (P = 0.05). A moderate but progressive increase in BMD of the spine (10.0% +/- 1.5% at 4 years) was found for MFP plus calcium compared with calcium only (P < 0.001), whereas the more modest increase in BMD of the total hip seen with MFP plus calcium (1.8% +/- 0.6%) did not differ from the increase seen with calcium only. CONCLUSIONS: Low-dose fluoride (20 mg/d) given continuously with calcium for prolonged periods can decrease vertebral fracture rates compared with calcium alone in patients with mild to moderate osteoporosis. [less ▲]

Detailed reference viewed: 11 (4 ULg)
Peer Reviewed
See detailTherapy for Osteoporosis. Miscellaneous and Experimental Agents
Reginster, Jean-Yves ULg; Taquet, A. N.; Gosset, Christiane ULg

in Endocrinology & Metabolism Clinics of North America (1998), 27(2), 453-63

None of the currently available medications for osteoporosis have demonstrated an ability to fully prevent the occurrence of new vertebral or peripheral osteoporotic fractures once the disease is ... [more ▼]

None of the currently available medications for osteoporosis have demonstrated an ability to fully prevent the occurrence of new vertebral or peripheral osteoporotic fractures once the disease is established. Several new therapies, therefore, are currently being developed to optimize the risk/benefit ratio of osteoporosis treatment. This article discusses a number of treatments currently being considered, including anabolic steroids, growth hormone or insulin-like growth factors, ipriflavone, parathyroid peptides, and strontium. Several other compounds have been suggested recently for treatment of osteoporosis and other are at very early stages of their development. In addition to pharmacologic approaches to the treatment of osteoporosis, hip protectors also may reduce hip fractures. [less ▲]

Detailed reference viewed: 8 (3 ULg)
Full Text
Peer Reviewed
See detailLes thérapeutiques à visée spécifiquement osseuse dans le traitement de l'ostéoporose postménopausique. Aspects pharmaco-économiques
Reginster, Jean-Yves ULg; Ben Sedrine, Wafa ULg; Gosset, Christiane ULg

in Revue Médicale de Liège (1998), 53(5), 290-293

Fairly new economic evaluations were, so far, properly conducted in the field of prevention and treatment of osteoporosis. This lack of studies is likely to be related to the pathophysiology and the ... [more ▼]

Fairly new economic evaluations were, so far, properly conducted in the field of prevention and treatment of osteoporosis. This lack of studies is likely to be related to the pathophysiology and the natural course of the disease, the small number of disease-specific instruments allowing the evaluation of quality of life changes following fractures and the frequent interaction of osteoporotic treatments with other body systems. Notwithstanding a lot of efforts have to be brought before economic evaluations in osteoporosis become a key determinant of Public Health strategies, it remains of prime interest to promote this type of research taking into account the importance of the social, human and economic burden of this disease. [less ▲]

Detailed reference viewed: 35 (17 ULg)
Peer Reviewed
See detailParathyroid hormone plasma concentration in response to low 25-OH vitamin D circulating levels increase with age in elderly women
DEROISY, Rita ULg; Taquet, AN; Dewe, W et al

in Osteoporosis International (1998), 8(S3), 40

Detailed reference viewed: 16 (1 ULg)
Peer Reviewed
See detailThe role of the general practitioner in the provision of palliative care
Devos, M; Reginster-Haneuse, G; Gosset, Christiane ULg et al

Conference (1998)

Detailed reference viewed: 5 (0 ULg)
Peer Reviewed
See detailCase Management : a multidisciplinary approach to prevent institutionalization of high-risk elderly
Moons, P; Borgermans, L; Milisen, K et al

Conference (1998)

Detailed reference viewed: 6 (0 ULg)
See detailAu-delà des consommations individuelles, quelle prévention en santé mentale ?
Gosset, Christiane ULg

in Actes du Colloque “ Alcool, cannabis, ecstasy, … entre liberté individuelle et vie sociale, … qui fait autorité ?" (1998)

Detailed reference viewed: 5 (1 ULg)